C S Duvernoy
Affiliation: University of Michigan
- Coronary heart disease in women: what do we know now?Claire S Duvernoy
University of Michigan School of Medicine, Acting Chief, Cardiology Section, VA Ann Arbor Healthcare System and, Director, University of Michigan Health System, Women s Heart Program, 2215 Fuller Road, Box 111A, Ann Arbor, MI 48105 2399, USA
Future Cardiol 1:617-28. 2005..Emerging data suggest that coronary heart disease may be a different entity in women compared with men, requiring different preventive, diagnostic and treatment strategies...
- Evolving strategies for the treatment of microvascular angina in womenClaire S Duvernoy
Cardiology Section, Veterans Affairs Ann Arbor Healthcare System, Department of Internal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, MI, USA
Expert Rev Cardiovasc Ther 10:1413-9. 2012..Nitrates may be effective for symptom relief. Further studies are required to determine whether specific treatments are associated with improved survival as well as decreased symptoms...
- Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trialClaire S Duvernoy
VA Ann Arbor Healthcare System University of Michigan, Ann Arbor, Michigan 48105 2399, USA
J Womens Health (Larchmt) 19:1459-65. 2010..This analysis examines the effects of concomitant antiplatelet therapy on VTE risk in raloxifene-treated women...
- Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: an analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registryClaire S Duvernoy
University of Michigan Medical Center, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48105 2399, USA
Am Heart J 159:677-683.e1. 2010..Prior studies have shown a relationship between female gender and adverse outcomes after percutaneous coronary interventions (PCIs). Whether this relationship still exists with contemporary PCI remains to be determined...
- Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot studyClaire S Duvernoy
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48105, USA
J Womens Health (Larchmt) 16:963-70. 2007....
- Self-reported physical activity and myocardial flow reserve in postmenopausal women at risk for cardiovascular diseaseClaire S Duvernoy
Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
J Womens Health (Larchmt) 15:45-50. 2006..Regular exercise protects against coronary heart disease (CHD) events and improves vascular reactivity. Exercise effects on myocardial flow reserve (MFR) are not well studied...
- Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifeneClaire S Duvernoy
VA Medical Center, University of Michigan Department of Internal Medicine, Division of Cardiology, Ann Arbor, MI 48105, USA
Menopause 12:444-52. 2005....
- Myocardial blood flow and flow reserve in response to hormone therapy in postmenopausal women with risk factors for coronary diseaseC Duvernoy
Division of Cardiology, University of Michigan, Ann Arbor, Michigan 48109, USA
J Clin Endocrinol Metab 89:2783-8. 2004..Further study is needed to clarify the effects of CHT on the endothelium of women with presumably diseased vasculature...
- The role of nitrogen 13 ammonia positron emission tomography in predicting functional outcome after coronary revascularizationC S Duvernoy
Department of Internal Medicine, University of Michigan, Ann Arbor, USA
J Nucl Cardiol 2:499-506. 1995..Previous studies have suggested a quantitative threshold for perfusion as evaluated by PET that separates scar from viable tissue...
- Weight changes and obesity predict impaired resting and endothelium-dependent myocardial blood flow in postmenopausal womenJulie W Martin
Cardiology Division, University of Michigan, Ann Arbor, Michigan, USA
Clin Cardiol 28:13-8. 2005..Obesity has been associated with impaired endothelial function, but the influence of lifetime weight patterns on endothelial function has not been studied...
- Symptoms of men and women presenting with acute coronary syndromesCynthia Arslanian-Engoren
School of Nursing, University of Michigan, Ann Arbor, Michigan, USA
Am J Cardiol 98:1177-81. 2006..In conclusion, gender should be considered when evaluating patients with symptoms of ACS...
- Competitive bidding for interventional cardiology supplies: lessons learned during round 2Kim A Eagle
Department of Internal Medicine, University of Michigan Health System, Ann Arbor, USA
Am J Manag Care 8:384-8. 2002..To assess the magnitude of savings and develop concepts for "best strategies" in reducing costs in the purchasing of high-technology, high-cost materials used in coronary interventions and electrophysiologic treatments...
- Cardiovascular risk, obesity, and myocardial blood flow in postmenopausal womenApurva A Motivala
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
J Nucl Cardiol 15:510-7. 2008..Whether this is because of obesity itself or the accompanying increase in cardiovascular risk factors (CRFs) remains controversial...
- Stent placement for coronary stenosis in Kawasaki disease: case report and literature reviewElias A Iliadis
University of Michigan Health System, Department of Internal Medicine, Division of Cardiology, Veterans Affairs Medical Center, 2215 Fuller Road, Box 111A, Ann Arbor, MI 48015, USA
J Interv Cardiol 15:29-31. 2002..This case illustrates the complementary nature of percutaneous and surgical myocardial revascularization strategies in appropriately selected patients with Kawasaki disease...
- Hormone replacement therapy trials: an updateClaire S Duvernoy
Preventive Cardiology, New York Presbyterian Hospital, 622 West 168th Street, PH 10 203B, New York, NY 10032, USA
Curr Atheroscler Rep 4:156-60. 2002..Several alternatives to HRT, including phytoestrogens and selective estrogen receptor modulators, have favorable effects on cardiovascular risk factors, but their impact on clinical outcomes remains to be determined...